For decades, river blindness has retreated before sustained treatment campaigns across West Africa, yet the tools to confirm its absence have lagged behind the ambition to erase it. Two new rapid blood tests, evaluated among 1,700 people in seven Ghanaian communities, now offer field workers a faster, more accessible way to map where Onchocerca volvulus still circulates — a meaningful step, though not yet the final one. The tests meet the World Health Organization's threshold for disease mapping but fall short of the higher certainty required to stop mass treatment, reminding us that the last
New rapid tests show promise for onchocerciasis elimination mapping in Ghana
Success at eliminating disease makes it harder to prove you've succeeded
Mark
So these tests work by finding antibodies. How does that differ from finding the actual parasite?
Mimi
Antibodies are the immune system's memory of infection. They persist even after the worms are gone, which is useful for mapping but problematic if you're trying to confirm someone is truly cured.
Luke
That's the real limitation here. The tests are detecting past exposure, not necessarily active infection. The O-150 qPCR looks for parasite DNA directly, which is more specific to current infection—but it only found 26 positives in 1,700 people.
Mark
Why so few?
Mimi
Because these communities have been treated for years. The disease is rare now. That's actually a sign of success, but it makes validation nearly impossible.
Luke
Exactly. You can't properly test a diagnostic when you have almost no true positives. The confidence intervals are huge. The sensitivity could be anywhere from 48 to 91 percent depending on which test and setting you look at.
Mark
But the tests still met WHO requirements for mapping?
Mimi
For mapping, yes. You're trying to find any remaining pockets of transmission. These tests are good enough for that. But for stopping treatment—for saying "we're done, this disease is gone"—you need much higher certainty.
Luke
And that's where the story gets honest. The researchers are saying we need better diagnostics, but they're also admitting that in elimination settings, you may never have enough infected people to properly validate them.
Mark
So what happens next?
Mimi
Programs keep using these tests for surveillance and mapping. Meanwhile, researchers keep trying to develop something that can definitively prove elimination.
Luke
The real question is whether that's even possible with an antibody-based test. You might need something that detects active parasites or their current products, not just the immune memory.
The Pulse
- River blindness elimination programs have long been hampered by diagnostics that cannot reliably distinguish a community that has cleared infection from one where the parasite still hides at low levels.
- Two new lateral flow assays — DDTDc and BA/GADx — were deployed across seven Ghanaian communities, testing whether simpler, field-ready tools could close that gap with only a finger prick of blood.
- Sensitivities of 69–77% and specificities of 68–73% outpaced or matched the existing standard test, and concordance above 92% with established methods signals these tools are genuinely useful — but the scarcity of confirmed infections in near-elimination settings left wide uncertainty around the results.
- Both tests cleared the WHO bar for mapping active transmission zones, giving elimination programs a practical new instrument for deciding where treatment is still needed.
- Neither test, however, reached the higher threshold required to justify stopping mass drug administration — the most consequential decision in any elimination campaign — leaving that critical diagnostic gap still open.
For decades, river blindness has retreated before sustained treatment campaigns across West Africa, yet the tools to confirm its absence have lagged behind the ambition to erase it. Two new rapid blood tests, evaluated among 1,700 people in seven Ghanaian communities, now offer field workers a faster, more accessible way to map where Onchocerca volvulus still circulates — a meaningful step, though not yet the final one. The tests meet the World Health Organization's threshold for disease mapping but fall short of the higher certainty required to stop mass treatment, reminding us that the last mile of elimination demands its own kind of precision.
River blindness has been in retreat across parts of Africa for decades, but the tools used to confirm its absence have never quite kept pace. Existing diagnostics struggle to determine whether a community has truly cleared Onchocerca volvulus or whether the parasite persists at levels too low to easily detect. Two new rapid blood tests were brought to seven Ghanaian communities to see whether they could do better.
The first, DDTDc, was developed by Drugs and Diagnostics for Tropical Diseases; the second, BA/GADx, by Bioaster and Global Access Diagnostics. Both detect IgG4 antibodies the body produces in response to the parasite, and both can be performed at the point of care using a finger prick or a dried blood spot processed later in a laboratory. Researchers enrolled 1,700 people aged five and older across communities that had either received years of mass drug administration or were considered disease-free.
The results told a story of partial success. DDTDc detected between 69 and 77 percent of true infections; BA/GADx performed similarly at 69 to 71 percent. Both were reasonably specific, and both agreed with the existing SD Ov16 rapid test more than 92 percent of the time — a meaningful alignment. Yet a crucial limitation shadowed the findings: across all 1,700 participants, only 26 confirmed infections were identified. In a near-elimination setting, so few true positives make it difficult to assess a test's real-world performance with confidence.
The World Health Organization requires different levels of diagnostic certainty for different program decisions. Both new tests met the threshold for mapping — determining where active transmission still occurs and treatment is still needed. Neither met the higher bar required for stopping mass drug administration, the moment when a program declares a region free and withdraws preventive treatment. That decision demands a confidence these tests, as currently validated, cannot yet provide.
The research marks genuine progress: practical, field-ready tools that bring onchocerciasis surveillance closer to communities and further from laboratory dependency. But it also illuminates a paradox at the heart of elimination work — the more successful a program becomes, the harder it is to validate the diagnostics needed to finish the job, because so few infected people remain to test against. The path to confidently declaring a region free of river blindness remains open, and the science of detection must keep pace with the shrinking target.
Onchocerciasis—river blindness—has been a target for elimination in parts of Africa for decades, but the tools used to track progress have always been imperfect. Existing diagnostic methods lack the sensitivity and specificity needed to reliably tell whether a community has truly cleared the infection or whether the parasite still lurks beneath the surface. Two new rapid blood tests, developed by separate research teams, were put to work in seven Ghanaian communities to see whether they could do better.
The first test, called DDTDc (Biplex Version C), comes from Drugs and Diagnostics for Tropical Diseases. The second, BA/GADx, was developed by Bioaster and Global Access Diagnostics. Both work by detecting antibodies in blood—specifically, IgG4 antibodies that the body produces in response to Onchocerca volvulus, the parasitic worm that causes the disease. The DDTDc test detects two different parasite antigens; the BA/GADx test focuses on one. The appeal of both is simplicity: they can be performed at the point of care, using either a finger prick of whole blood or a dried blood spot collected in the field and analyzed later in a lab.
Researchers enrolled 1,700 people aged five and older across the seven communities—areas that had either received years of mass drug administration or were considered free of the disease altogether. The new tests were run on blood samples collected in the field and on dried blood spots processed in the laboratory. To see how accurate they were, the results were compared against two reference standards: a molecular test called O-150 qPCR performed on skin snips, and an existing rapid test called SD Ov16 RDT.
The numbers tell a story of partial success. The DDTDc test caught between 69 and 77 percent of true infections, depending on whether it was used in the field or the lab. The BA/GADx test performed similarly, with sensitivity ranging from 69 to 71 percent. Both tests were also reasonably specific—correctly identifying people without infection—ranging from 68 to 73 percent. These figures were better than or comparable to the existing SD Ov16 RDT, which showed 65 percent sensitivity. When the researchers looked at how often the new tests agreed with the existing test, they found concordance above 92 percent. Statistical measures of agreement (Kappa values) ranged from 0.63 to 0.79, indicating substantial alignment.
But there is a crucial caveat buried in the results. The reference standard—the O-150 qPCR test on skin snips—identified only 26 positive cases across all 1,700 participants. In a disease elimination setting, where prevalence has already been driven very low, this scarcity of confirmed infections makes it difficult to fully assess how well a new test performs. The researchers had few true positives to work with, which means the confidence intervals around their sensitivity estimates are wide, and the real-world performance of these tests in detecting the last remaining infections remains somewhat uncertain.
The World Health Organization has set specific performance targets for diagnostic tools used in onchocerciasis programs. Both new tests met the requirements for mapping decisions—determining whether a region still has active transmission and needs continued treatment. Neither test, however, met the higher bar needed for stopping mass drug administration. That decision requires greater confidence that the infection has truly been eliminated, and these tests, as currently validated, cannot provide it. The researchers note that this reflects a deeper challenge: in low-prevalence settings, the very success of elimination efforts makes it harder to validate new diagnostics, because there are so few infected people left to test against.
The work represents tangible progress. Both tests proved practical to use in the field, required only a small blood sample, and delivered results that aligned well with existing methods. For programs trying to map where onchocerciasis still circulates in West Africa, these tools offer a faster, more accessible alternative to skin snips and molecular testing. But the path to a diagnostic that can confidently declare a region free of the disease—and justify stopping preventive treatment—remains open. The research underscores that eliminating a disease is not just a matter of treatment; it requires diagnostic innovation that keeps pace with the shrinking target.
Notable Quotes
Both tests demonstrated field usability and adequate sensitivity, meeting WHO TPP requirements for onchocerciasis mapping decisions but not for MDA stopping decisions.— Study findings
The need for continued diagnostic innovation to address the challenges of evaluating new diagnostic tests in disease elimination settings with a low number of true positives.— Study conclusion
Want the full story?
Read the original at Nature ↗
Health & Medicine